Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 1/20 | 0.52 |
| ▸ | NSD2 | O96028 | 2/20 | 0.45 |
| ▸ | G6PD | P11413 | 2/20 | 0.45 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TYMS | P04818 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30442162 | 1.00 | S100A4 (0.52) | S100A4NSD2G6PDDNMT1ALOX15 | |
| SCHEMBL8560870 | 0.75 | ALOX15 (0.41) | ALOX15TDP1TYMSALDH1A1 | |
| SCHEMBL30450925 | 0.75 | ALOX15 (0.41) | NSD2G6PDDNMT1ALOX15TDP1 | |
| SCHEMBL8659590 | 0.75 | NSD2 (0.41) | NSD2ALOX15TDP1TYMSALDH1A1 | |
| SCHEMBL26732582 | 0.75 | ALOX15 (0.41) | NSD2G6PDDNMT1ALOX15TDP1 | |
| SCHEMBL24834521 | 0.75 | ALOX15 (0.37) | ALOX15TDP1TYMSCYP2C19RAB9A | |
| SCHEMBL10473824 | 0.75 | ALOX15 (0.37) | ALOX15TDP1TYMSALDH1A1 | |
| SCHEMBL9589827 | 0.73 | CYP3A4 (0.41) | ALOX15TDP1TYMSALDH1A1 | |
| SCHEMBL3722975 | 0.73 | S100A4 (0.59) | S100A4NSD2G6PDDNMT1CYP2C19 | |
| Water SCHEMBL10372295 | 0.71 | NSD2 (0.58) | S100A4NSD2G6PDDNMT1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503445-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2025-12-23 | — | — | US | disclosed |
| EP-4628490-A2 | NLRP3 INFLAMMASOME INHIBITORS | Astrazeneca AB (SE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4363406-B1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2025-09-10 | — | — | EP | disclosed |
| EP-3676261-B1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LTD (GB) | 2024-12-18 | — | — | EP | disclosed |
| US-20240383862-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-11-21 | — | — | US | disclosed |
| WO-2024141535-A1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | WO | disclosed |
| EP-4363406-A1 | NLRP3 INFLAMMASOME INHIBITORS | Astrazeneca AB (SE) | 2024-05-08 | — | — | EP | disclosed |
| US-11970463-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2024-04-30 | — | — | US | disclosed |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | CHRONOS THERAPEUTICS LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| WO-2023086799-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS | VIGIL NEUROSCIENCE, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-6683213-B1 | CHEMICAL INTERMEDIATES FOR PYRIDINEDICARBOXAMIDE HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2004-01-27 | — | — | US | disclosed |
| EP-0839145-B1 | HETEROCYCLYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2003-11-05 | — | — | EP | disclosed |
| US-6472349-B1 | Pyridine-2,3-dicarboxylic acid diamides | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-29 | — | — | US | disclosed |
| CN-1349507-A | Pyridine-2,3-dicarboxylic acid diamides | BASF AG (DE) | 2002-05-15 | — | — | CN | disclosed |
| US-5935973-A | AFFINITY FOR 5-HT1A, ALPHA1, ALPHA2 AND/OR D2 RECEPTORS; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS, PSYCHOSES, DYSKINESIAS, PARKINSON'S DISEASE, HYPOTENSIVE AGENTS, TOURETTE'S SYNDROME, OBSESSIVE-COMPULSIVE BEHAVIOUR, PANIC ATTACKS, SOCIAL PHOBIAS | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-08-10 | — | — | US | disclosed |
| EP-0839145-A1 | HETEROCYCLYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | Knoll AG (DE) | 1998-05-06 | — | — | EP | disclosed |
| WO-1997003071-A1 | HETEROCYCLYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1997-01-30 | — | — | WO | disclosed |
| US-5262387-A | Pyridine derivatives and their use for controlling undesirable plant growth | BASF AKTIENGESELLSCHAFT (DE) | 1993-11-16 | — | — | US | disclosed |
| US-5262384-A | Herbicides | BASF AKTIENGESELLSCHAFT (DE) | 1993-11-16 | — | — | US | disclosed |
| EP-0508800-A1 | New Herbicides | RHONE POULENC AGRICULTURE LTD. (GB) | 1992-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383862-A1 | COMPOUNDS AND THEIR USE | NLRP3, PYCARD, NLRP1 | S100A4 2839/4885NSD2 1968/4885G6PD 2387/4885 |
| US-11970463-B2 | Compounds and their use | NLRP3, PYCARD, NLRP1 | S100A4 2839/4885NSD2 1968/4885G6PD 2387/4885 |
| US-12503445-B2 | Compounds and their use | NLRP3, PYCARD, NLRP1 | S100A4 2839/4885NSD2 1968/4885G6PD 2387/4885 |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | HCRTR2, HCRTR1, NPY1R | S100A4 4690/4885NSD2 3510/4885G6PD 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.